Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
Backgrounds Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn’s disease (CD). We aimed to identify the optimal UST trough levels predicting clinical, laboratory and endoscopic remission in CD patients. Methods Twenty-eight patients wi...
Saved in:
| Published in | BMC gastroenterology Vol. 22; no. 1; pp. 195 - 9 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
21.04.2022
BioMed Central Ltd Springer Nature B.V BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1471-230X 1471-230X |
| DOI | 10.1186/s12876-022-02271-4 |
Cover
| Abstract | Backgrounds
Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn’s disease (CD). We aimed to identify the optimal UST trough levels predicting clinical, laboratory and endoscopic remission in CD patients.
Methods
Twenty-eight patients with CD were enrolled and investigated (27 patients by enteroscopy and 1 by colonoscopy). The endoscopic activity was assessed using the scoring system that applied the Rutgeerts score to observed intestine. Serum UST trough levels and anti-UST antibodies (AUAs) levels were determined by in-house immunoassays.
Results
Endoscopic activity was negatively correlated with serum UST trough levels (Spearman’s rank correlation coefficient (ρ) = − 0.66,
P
= 0.0001) and serum albumin levels (ρ = − 0.60,
P
= 0.0007). The endoscopic activity was positively and significantly correlated with CRP (ρ = 0.59,
P
= 0.0009) and ESR (ρ = 0.44,
P
= 0.033). There was no significant association between the endoscopic score and AUA levels and/or Crohn’s disease activity index (CDAI). Serum UST trough levels and albumin levels were significantly higher in the endoscopic remission group (scores of 0 and 1) than in the non-endoscopic remission group (UST trough, mean 3.3 vs. 1.8 μg/mL). No significant difference was observed in AUAs between the endoscopic remission and non-remission groups. Receiver operation curve (ROC) analysis revealed that the optimal cutoff value of UST trough levels predicting normal CRP and serum albumin levels was 1.7 μg/mL for each, and the optimal cutoff value predicting endoscopic remission was 2.0 μg/mL (AUC: 0.80, 95% CI 0.64–0.96).
Conclusion
Achievement of endoscopic remission requires higher UST trough levels than required for normalization of CRP and serum albumin levels. |
|---|---|
| AbstractList | Backgrounds
Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn’s disease (CD). We aimed to identify the optimal UST trough levels predicting clinical, laboratory and endoscopic remission in CD patients.
Methods
Twenty-eight patients with CD were enrolled and investigated (27 patients by enteroscopy and 1 by colonoscopy). The endoscopic activity was assessed using the scoring system that applied the Rutgeerts score to observed intestine. Serum UST trough levels and anti-UST antibodies (AUAs) levels were determined by in-house immunoassays.
Results
Endoscopic activity was negatively correlated with serum UST trough levels (Spearman’s rank correlation coefficient (ρ) = − 0.66,
P
= 0.0001) and serum albumin levels (ρ = − 0.60,
P
= 0.0007). The endoscopic activity was positively and significantly correlated with CRP (ρ = 0.59,
P
= 0.0009) and ESR (ρ = 0.44,
P
= 0.033). There was no significant association between the endoscopic score and AUA levels and/or Crohn’s disease activity index (CDAI). Serum UST trough levels and albumin levels were significantly higher in the endoscopic remission group (scores of 0 and 1) than in the non-endoscopic remission group (UST trough, mean 3.3 vs. 1.8 μg/mL). No significant difference was observed in AUAs between the endoscopic remission and non-remission groups. Receiver operation curve (ROC) analysis revealed that the optimal cutoff value of UST trough levels predicting normal CRP and serum albumin levels was 1.7 μg/mL for each, and the optimal cutoff value predicting endoscopic remission was 2.0 μg/mL (AUC: 0.80, 95% CI 0.64–0.96).
Conclusion
Achievement of endoscopic remission requires higher UST trough levels than required for normalization of CRP and serum albumin levels. Backgrounds Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn’s disease (CD). We aimed to identify the optimal UST trough levels predicting clinical, laboratory and endoscopic remission in CD patients. Methods Twenty-eight patients with CD were enrolled and investigated (27 patients by enteroscopy and 1 by colonoscopy). The endoscopic activity was assessed using the scoring system that applied the Rutgeerts score to observed intestine. Serum UST trough levels and anti-UST antibodies (AUAs) levels were determined by in-house immunoassays. Results Endoscopic activity was negatively correlated with serum UST trough levels (Spearman’s rank correlation coefficient (ρ) = − 0.66, P = 0.0001) and serum albumin levels (ρ = − 0.60, P = 0.0007). The endoscopic activity was positively and significantly correlated with CRP (ρ = 0.59, P = 0.0009) and ESR (ρ = 0.44, P = 0.033). There was no significant association between the endoscopic score and AUA levels and/or Crohn’s disease activity index (CDAI). Serum UST trough levels and albumin levels were significantly higher in the endoscopic remission group (scores of 0 and 1) than in the non-endoscopic remission group (UST trough, mean 3.3 vs. 1.8 μg/mL). No significant difference was observed in AUAs between the endoscopic remission and non-remission groups. Receiver operation curve (ROC) analysis revealed that the optimal cutoff value of UST trough levels predicting normal CRP and serum albumin levels was 1.7 μg/mL for each, and the optimal cutoff value predicting endoscopic remission was 2.0 μg/mL (AUC: 0.80, 95% CI 0.64–0.96). Conclusion Achievement of endoscopic remission requires higher UST trough levels than required for normalization of CRP and serum albumin levels. Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn's disease (CD). We aimed to identify the optimal UST trough levels predicting clinical, laboratory and endoscopic remission in CD patients. Twenty-eight patients with CD were enrolled and investigated (27 patients by enteroscopy and 1 by colonoscopy). The endoscopic activity was assessed using the scoring system that applied the Rutgeerts score to observed intestine. Serum UST trough levels and anti-UST antibodies (AUAs) levels were determined by in-house immunoassays. Endoscopic activity was negatively correlated with serum UST trough levels (Spearman's rank correlation coefficient ([rho]) = - 0.66, P = 0.0001) and serum albumin levels ([rho] = - 0.60, P = 0.0007). The endoscopic activity was positively and significantly correlated with CRP ([rho] = 0.59, P = 0.0009) and ESR ([rho] = 0.44, P = 0.033). There was no significant association between the endoscopic score and AUA levels and/or Crohn's disease activity index (CDAI). Serum UST trough levels and albumin levels were significantly higher in the endoscopic remission group (scores of 0 and 1) than in the non-endoscopic remission group (UST trough, mean 3.3 vs. 1.8 [mu]g/mL). No significant difference was observed in AUAs between the endoscopic remission and non-remission groups. Receiver operation curve (ROC) analysis revealed that the optimal cutoff value of UST trough levels predicting normal CRP and serum albumin levels was 1.7 [mu]g/mL for each, and the optimal cutoff value predicting endoscopic remission was 2.0 [mu]g/mL (AUC: 0.80, 95% CI 0.64-0.96). Achievement of endoscopic remission requires higher UST trough levels than required for normalization of CRP and serum albumin levels. Abstract Backgrounds Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn’s disease (CD). We aimed to identify the optimal UST trough levels predicting clinical, laboratory and endoscopic remission in CD patients. Methods Twenty-eight patients with CD were enrolled and investigated (27 patients by enteroscopy and 1 by colonoscopy). The endoscopic activity was assessed using the scoring system that applied the Rutgeerts score to observed intestine. Serum UST trough levels and anti-UST antibodies (AUAs) levels were determined by in-house immunoassays. Results Endoscopic activity was negatively correlated with serum UST trough levels (Spearman’s rank correlation coefficient (ρ) = − 0.66, P = 0.0001) and serum albumin levels (ρ = − 0.60, P = 0.0007). The endoscopic activity was positively and significantly correlated with CRP (ρ = 0.59, P = 0.0009) and ESR (ρ = 0.44, P = 0.033). There was no significant association between the endoscopic score and AUA levels and/or Crohn’s disease activity index (CDAI). Serum UST trough levels and albumin levels were significantly higher in the endoscopic remission group (scores of 0 and 1) than in the non-endoscopic remission group (UST trough, mean 3.3 vs. 1.8 μg/mL). No significant difference was observed in AUAs between the endoscopic remission and non-remission groups. Receiver operation curve (ROC) analysis revealed that the optimal cutoff value of UST trough levels predicting normal CRP and serum albumin levels was 1.7 μg/mL for each, and the optimal cutoff value predicting endoscopic remission was 2.0 μg/mL (AUC: 0.80, 95% CI 0.64–0.96). Conclusion Achievement of endoscopic remission requires higher UST trough levels than required for normalization of CRP and serum albumin levels. Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn's disease (CD). We aimed to identify the optimal UST trough levels predicting clinical, laboratory and endoscopic remission in CD patients. Twenty-eight patients with CD were enrolled and investigated (27 patients by enteroscopy and 1 by colonoscopy). The endoscopic activity was assessed using the scoring system that applied the Rutgeerts score to observed intestine. Serum UST trough levels and anti-UST antibodies (AUAs) levels were determined by in-house immunoassays. Endoscopic activity was negatively correlated with serum UST trough levels (Spearman's rank correlation coefficient (ρ) = - 0.66, P = 0.0001) and serum albumin levels (ρ = - 0.60, P = 0.0007). The endoscopic activity was positively and significantly correlated with CRP (ρ = 0.59, P = 0.0009) and ESR (ρ = 0.44, P = 0.033). There was no significant association between the endoscopic score and AUA levels and/or Crohn's disease activity index (CDAI). Serum UST trough levels and albumin levels were significantly higher in the endoscopic remission group (scores of 0 and 1) than in the non-endoscopic remission group (UST trough, mean 3.3 vs. 1.8 μg/mL). No significant difference was observed in AUAs between the endoscopic remission and non-remission groups. Receiver operation curve (ROC) analysis revealed that the optimal cutoff value of UST trough levels predicting normal CRP and serum albumin levels was 1.7 μg/mL for each, and the optimal cutoff value predicting endoscopic remission was 2.0 μg/mL (AUC: 0.80, 95% CI 0.64-0.96). Achievement of endoscopic remission requires higher UST trough levels than required for normalization of CRP and serum albumin levels. Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn's disease (CD). We aimed to identify the optimal UST trough levels predicting clinical, laboratory and endoscopic remission in CD patients.BACKGROUNDSOptimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn's disease (CD). We aimed to identify the optimal UST trough levels predicting clinical, laboratory and endoscopic remission in CD patients.Twenty-eight patients with CD were enrolled and investigated (27 patients by enteroscopy and 1 by colonoscopy). The endoscopic activity was assessed using the scoring system that applied the Rutgeerts score to observed intestine. Serum UST trough levels and anti-UST antibodies (AUAs) levels were determined by in-house immunoassays.METHODSTwenty-eight patients with CD were enrolled and investigated (27 patients by enteroscopy and 1 by colonoscopy). The endoscopic activity was assessed using the scoring system that applied the Rutgeerts score to observed intestine. Serum UST trough levels and anti-UST antibodies (AUAs) levels were determined by in-house immunoassays.Endoscopic activity was negatively correlated with serum UST trough levels (Spearman's rank correlation coefficient (ρ) = - 0.66, P = 0.0001) and serum albumin levels (ρ = - 0.60, P = 0.0007). The endoscopic activity was positively and significantly correlated with CRP (ρ = 0.59, P = 0.0009) and ESR (ρ = 0.44, P = 0.033). There was no significant association between the endoscopic score and AUA levels and/or Crohn's disease activity index (CDAI). Serum UST trough levels and albumin levels were significantly higher in the endoscopic remission group (scores of 0 and 1) than in the non-endoscopic remission group (UST trough, mean 3.3 vs. 1.8 μg/mL). No significant difference was observed in AUAs between the endoscopic remission and non-remission groups. Receiver operation curve (ROC) analysis revealed that the optimal cutoff value of UST trough levels predicting normal CRP and serum albumin levels was 1.7 μg/mL for each, and the optimal cutoff value predicting endoscopic remission was 2.0 μg/mL (AUC: 0.80, 95% CI 0.64-0.96).RESULTSEndoscopic activity was negatively correlated with serum UST trough levels (Spearman's rank correlation coefficient (ρ) = - 0.66, P = 0.0001) and serum albumin levels (ρ = - 0.60, P = 0.0007). The endoscopic activity was positively and significantly correlated with CRP (ρ = 0.59, P = 0.0009) and ESR (ρ = 0.44, P = 0.033). There was no significant association between the endoscopic score and AUA levels and/or Crohn's disease activity index (CDAI). Serum UST trough levels and albumin levels were significantly higher in the endoscopic remission group (scores of 0 and 1) than in the non-endoscopic remission group (UST trough, mean 3.3 vs. 1.8 μg/mL). No significant difference was observed in AUAs between the endoscopic remission and non-remission groups. Receiver operation curve (ROC) analysis revealed that the optimal cutoff value of UST trough levels predicting normal CRP and serum albumin levels was 1.7 μg/mL for each, and the optimal cutoff value predicting endoscopic remission was 2.0 μg/mL (AUC: 0.80, 95% CI 0.64-0.96).Achievement of endoscopic remission requires higher UST trough levels than required for normalization of CRP and serum albumin levels.CONCLUSIONAchievement of endoscopic remission requires higher UST trough levels than required for normalization of CRP and serum albumin levels. Backgrounds Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn's disease (CD). We aimed to identify the optimal UST trough levels predicting clinical, laboratory and endoscopic remission in CD patients. Methods Twenty-eight patients with CD were enrolled and investigated (27 patients by enteroscopy and 1 by colonoscopy). The endoscopic activity was assessed using the scoring system that applied the Rutgeerts score to observed intestine. Serum UST trough levels and anti-UST antibodies (AUAs) levels were determined by in-house immunoassays. Results Endoscopic activity was negatively correlated with serum UST trough levels (Spearman's rank correlation coefficient ([rho]) = - 0.66, P = 0.0001) and serum albumin levels ([rho] = - 0.60, P = 0.0007). The endoscopic activity was positively and significantly correlated with CRP ([rho] = 0.59, P = 0.0009) and ESR ([rho] = 0.44, P = 0.033). There was no significant association between the endoscopic score and AUA levels and/or Crohn's disease activity index (CDAI). Serum UST trough levels and albumin levels were significantly higher in the endoscopic remission group (scores of 0 and 1) than in the non-endoscopic remission group (UST trough, mean 3.3 vs. 1.8 [mu]g/mL). No significant difference was observed in AUAs between the endoscopic remission and non-remission groups. Receiver operation curve (ROC) analysis revealed that the optimal cutoff value of UST trough levels predicting normal CRP and serum albumin levels was 1.7 [mu]g/mL for each, and the optimal cutoff value predicting endoscopic remission was 2.0 [mu]g/mL (AUC: 0.80, 95% CI 0.64-0.96). Conclusion Achievement of endoscopic remission requires higher UST trough levels than required for normalization of CRP and serum albumin levels. Keywords: Ustekinumab, Therapeutic drug monitoring, Enteroscopy |
| ArticleNumber | 195 |
| Audience | Academic |
| Author | Inatomi, Osamu Andoh, Akira Hirayama, Hisashi Yoshida, Atsushi Imai, Takayuki Bamba, Shigeki Takahashi, Kenichiro Morita, Yasuhiro |
| Author_xml | – sequence: 1 givenname: Hisashi surname: Hirayama fullname: Hirayama, Hisashi organization: Department of Medicine, Shiga University of Medical Science – sequence: 2 givenname: Yasuhiro surname: Morita fullname: Morita, Yasuhiro organization: Department of Medicine, Shiga University of Medical Science – sequence: 3 givenname: Takayuki surname: Imai fullname: Imai, Takayuki organization: Department of Medicine, Shiga University of Medical Science – sequence: 4 givenname: Kenichiro surname: Takahashi fullname: Takahashi, Kenichiro organization: Department of Medicine, Shiga University of Medical Science – sequence: 5 givenname: Atsushi surname: Yoshida fullname: Yoshida, Atsushi organization: Center for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital – sequence: 6 givenname: Shigeki surname: Bamba fullname: Bamba, Shigeki organization: Department of Medicine, Shiga University of Medical Science – sequence: 7 givenname: Osamu surname: Inatomi fullname: Inatomi, Osamu organization: Department of Medicine, Shiga University of Medical Science – sequence: 8 givenname: Akira surname: Andoh fullname: Andoh, Akira email: andoh@belle.shiga-med.ac.jp organization: Department of Medicine, Shiga University of Medical Science |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35448957$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUstq3DAUNSWlebQ_0EURdNPNpHpYkr0phKGPQKCbBroTetmjiUdyJTthdv2N_l6_pHI8TTKhhCKEhHTOke4597g48MHboniN4ClCFXufEK44W0CMp8nRonxWHKEybzCB3w8e7A-L45TWECJeYfKiOCS0LKua8qPi6jIN9sr5cSMVGGIY2xXo7LXtEuijNU4PzregkypEOYS4BdIbYL0JSYfeaRDtxqXkggfOg14OzvohgRs3rMAyhpX__fNXAsYlK5N9WTxvZJfsq916Ulx--vht-WVx8fXz-fLsYqEZRcNCIWMqqBTlhhtEpDJNZajUDFFeMk2swRpCxSpqlGI1riix0NimlhwTwig5Kc5nXRPkWvTRbWTciiCduD0IsRUyDk53VkBtDVNlQ4jCJaVK1sRIzks5WYsYz1pk1hp9L7c3suvuBBEUUwxijkHkCMRtDKLMrA8zqx_VxhqdTYmy2_vK_o13K9GGa1FDzFnNssC7nUAMP0abBpFt1rbrpLdhTAIzWuIqo2GGvn0EXYcx-mxwRjFWVrhG7B7Vyly2803I7-pJVJxxiAhmkE1ap_9A5WFyzDp3X-Py-R7hzcNC7yr822AZUM0AHUNK0TZCuyG3SZjqdt3TJuJH1P9yfpdXymDf2njvxhOsP5A8BfU |
| CitedBy_id | crossref_primary_10_1093_crocol_otae071 crossref_primary_10_1016_j_hrtlng_2023_10_004 crossref_primary_10_1093_ibd_izae159 crossref_primary_10_1177_17562848241271980 crossref_primary_10_3390_jcm13030669 crossref_primary_10_5409_wjcp_v14_i1_100938 crossref_primary_10_1007_s40265_024_02115_3 crossref_primary_10_1093_crocol_otae033 crossref_primary_10_3748_wjg_v30_i22_2902 crossref_primary_10_1186_s12967_024_05427_w crossref_primary_10_3390_jcm13061539 crossref_primary_10_1097_MD_0000000000038804 crossref_primary_10_7759_cureus_29718 crossref_primary_10_1097_MCG_0000000000001978 crossref_primary_10_3389_fphar_2023_1180750 crossref_primary_10_1007_s00535_022_01882_8 crossref_primary_10_14309_crj_0000000000001520 crossref_primary_10_1016_j_dld_2024_01_189 crossref_primary_10_3390_biomedicines11123229 crossref_primary_10_1111_jgh_16895 |
| Cites_doi | 10.1016/j.cytogfr.2018.12.002 10.1056/NEJMoa1602773 10.1016/j.cgh.2021.03.028 10.1053/j.gastro.2008.07.014 10.1093/ibd/izy134 10.1111/jgh.14962 10.1056/NEJMoa1203572 10.1053/j.gastro.2020.12.052 10.1093/ecco-jcc/jjz110 10.3748/wjg.v27.i16.1828 10.1016/S0016-5107(04)01878-4 10.1016/j.cgh.2021.02.025 10.1016/S0140-6736(12)60026-9 10.3390/jcm10061242 10.1053/j.gastro.2018.01.043 10.1016/j.cgh.2019.03.037 10.1093/ecco-jcc/jjz008 10.1146/annurev-immunol-030409-101225 10.1111/j.0105-2896.2004.00214.x 10.1016/0016-5085(79)90384-6 10.1136/gut.30.7.983 10.1016/0016-5085(90)90613-6 10.1111/apt.16551 10.1038/ajg.2009.579 10.1007/s00535-021-01784-1 10.1016/j.jmb.2010.07.046 10.1016/j.cgh.2019.02.042 10.1111/apt.14030 10.1016/j.cgh.2017.03.032 10.1056/NEJMoa1900750 10.1053/j.gastro.2018.06.035 10.1007/s00535-013-0829-7 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7QR 7T5 7X7 7XB 88E 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH H94 K9. M0S M1P P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM ADTOC UNPAY DOA |
| DOI | 10.1186/s12876-022-02271-4 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 6 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-230X |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_0ced6b4f33b2455ba93da774a1287167 10.1186/s12876-022-02271-4 PMC9027696 A701326060 35448957 10_1186_s12876_022_02271_4 |
| Genre | Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7QP 7QR 7T5 7XB 8FD 8FK AZQEC DWQXO FR3 H94 K9. P64 PKEHL PQEST PQUKI PRINS 7X8 5PM 2VQ 4.4 ADTOC AHSBF C1A EJD H13 IPNFZ RIG UNPAY |
| ID | FETCH-LOGICAL-c651t-b1dd80bb57d7d13abdf8d5ac615746c3ed2c00b685dbb692853e0def9a7233653 |
| IEDL.DBID | BENPR |
| ISSN | 1471-230X |
| IngestDate | Tue Oct 14 18:41:27 EDT 2025 Sun Oct 26 04:04:13 EDT 2025 Tue Sep 30 17:10:17 EDT 2025 Fri Sep 05 08:09:54 EDT 2025 Tue Oct 07 05:20:16 EDT 2025 Mon Oct 20 22:34:19 EDT 2025 Mon Oct 20 16:48:15 EDT 2025 Thu Jan 02 22:55:52 EST 2025 Thu Apr 24 23:09:11 EDT 2025 Wed Oct 01 04:52:31 EDT 2025 Sat Sep 06 07:35:51 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Therapeutic drug monitoring Ustekinumab Enteroscopy |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c651t-b1dd80bb57d7d13abdf8d5ac615746c3ed2c00b685dbb692853e0def9a7233653 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2666482916?pq-origsite=%requestingapplication%&accountid=15518 |
| PMID | 35448957 |
| PQID | 2666482916 |
| PQPubID | 44673 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_0ced6b4f33b2455ba93da774a1287167 unpaywall_primary_10_1186_s12876_022_02271_4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9027696 proquest_miscellaneous_2654289020 proquest_journals_2666482916 gale_infotracmisc_A701326060 gale_infotracacademiconefile_A701326060 pubmed_primary_35448957 crossref_citationtrail_10_1186_s12876_022_02271_4 crossref_primary_10_1186_s12876_022_02271_4 springer_journals_10_1186_s12876_022_02271_4 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-04-21 |
| PublicationDateYYYYMMDD | 2022-04-21 |
| PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-21 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC gastroenterology |
| PublicationTitleAbbrev | BMC Gastroenterol |
| PublicationTitleAlternate | BMC Gastroenterol |
| PublicationYear | 2022 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | JK MacDonald (2271_CR12) 2016; 11 WJ Sandborn (2271_CR15) 2021; 20 WR Best (2271_CR23) 1979; 77 L Peyrin-Biroulet (2271_CR3) 2010; 105 S Restellini (2271_CR32) 2021; 10 K Takenaka (2271_CR30) 2021; 54 J Luo (2271_CR8) 2010; 402 B Verstockt (2271_CR21) 2019; 13 K Papamichael (2271_CR18) 2019; 17 A Cholapranee (2271_CR5) 2017; 45 M State (2271_CR29) 2021; 27 DC Baumgart (2271_CR1) 2012; 380 MF Neurath (2271_CR7) 2019; 45 M Daperno (2271_CR28) 2004; 60 OJ Adedokun (2271_CR17) 2018; 154 JY Mary (2271_CR27) 1989; 30 H Nakase (2271_CR4) 2021; 56 H Imaeda (2271_CR24) 2014; 49 CL Langrish (2271_CR6) 2004; 202 WJ Sandborn (2271_CR10) 2012; 367 SB Hanauer (2271_CR13) 2019; 14 R Battat (2271_CR20) 2017; 15 P Rutgeerts (2271_CR22) 2018; 155 RS Dalal (2271_CR33) 2021 Y Morita (2271_CR26) 2020; 35 A Kaser (2271_CR2) 2010; 28 N Soufflet (2271_CR19) 2019; 17 S Restellini (2271_CR16) 2018; 24 BE Sands (2271_CR14) 2019; 381 BG Feagan (2271_CR11) 2016; 375 S Soffer (2271_CR31) 2021; 161 P Rutgeerts (2271_CR25) 1990; 99 WJ Sandborn (2271_CR9) 2008; 135 |
| References_xml | – volume: 45 start-page: 1 year: 2019 ident: 2271_CR7 publication-title: Cytokine Growth Factor Rev doi: 10.1016/j.cytogfr.2018.12.002 – volume: 375 start-page: 1946 issue: 20 year: 2016 ident: 2271_CR11 publication-title: N Engl J Med doi: 10.1056/NEJMoa1602773 – year: 2021 ident: 2271_CR33 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2021.03.028 – volume: 135 start-page: 1130 issue: 4 year: 2008 ident: 2271_CR9 publication-title: Gastroenterology doi: 10.1053/j.gastro.2008.07.014 – volume: 24 start-page: 2165 issue: 10 year: 2018 ident: 2271_CR16 publication-title: Inflamm Bowel Dis doi: 10.1093/ibd/izy134 – volume: 35 start-page: 1163 issue: 7 year: 2020 ident: 2271_CR26 publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.14962 – volume: 367 start-page: 1519 issue: 16 year: 2012 ident: 2271_CR10 publication-title: N Engl J Med doi: 10.1056/NEJMoa1203572 – volume: 161 start-page: 1073 issue: 3 year: 2021 ident: 2271_CR31 publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.12.052 – volume: 14 start-page: 23 issue: 1 year: 2019 ident: 2271_CR13 publication-title: J Crohns Colitis doi: 10.1093/ecco-jcc/jjz110 – volume: 27 start-page: 1828 issue: 16 year: 2021 ident: 2271_CR29 publication-title: World J Gastroenterol doi: 10.3748/wjg.v27.i16.1828 – volume: 60 start-page: 505 issue: 4 year: 2004 ident: 2271_CR28 publication-title: Gastrointest Endosc doi: 10.1016/S0016-5107(04)01878-4 – volume: 20 start-page: 578 issue: 3 year: 2021 ident: 2271_CR15 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2021.02.025 – volume: 380 start-page: 1590 issue: 9853 year: 2012 ident: 2271_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(12)60026-9 – volume: 10 start-page: 1242 issue: 6 year: 2021 ident: 2271_CR32 publication-title: J Clin Med doi: 10.3390/jcm10061242 – volume: 154 start-page: 1660 issue: 6 year: 2018 ident: 2271_CR17 publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.01.043 – volume: 17 start-page: 1655 issue: 9 year: 2019 ident: 2271_CR18 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2019.03.037 – volume: 13 start-page: 864 issue: 7 year: 2019 ident: 2271_CR21 publication-title: J Crohns Colitis doi: 10.1093/ecco-jcc/jjz008 – volume: 28 start-page: 573 year: 2010 ident: 2271_CR2 publication-title: Annu Rev Immunol doi: 10.1146/annurev-immunol-030409-101225 – volume: 202 start-page: 96 year: 2004 ident: 2271_CR6 publication-title: Immunol Rev doi: 10.1111/j.0105-2896.2004.00214.x – volume: 77 start-page: 843 issue: 4 Pt 2 year: 1979 ident: 2271_CR23 publication-title: Gastroenterology doi: 10.1016/0016-5085(79)90384-6 – volume: 30 start-page: 983 issue: 7 year: 1989 ident: 2271_CR27 publication-title: Gut doi: 10.1136/gut.30.7.983 – volume: 99 start-page: 956 issue: 4 year: 1990 ident: 2271_CR25 publication-title: Gastroenterology doi: 10.1016/0016-5085(90)90613-6 – volume: 54 start-page: 1052 issue: 8 year: 2021 ident: 2271_CR30 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.16551 – volume: 105 start-page: 289 issue: 2 year: 2010 ident: 2271_CR3 publication-title: Am J Gastroenterol doi: 10.1038/ajg.2009.579 – volume: 56 start-page: 489 issue: 6 year: 2021 ident: 2271_CR4 publication-title: J Gastroenterol doi: 10.1007/s00535-021-01784-1 – volume: 402 start-page: 797 issue: 5 year: 2010 ident: 2271_CR8 publication-title: J Mol Biol doi: 10.1016/j.jmb.2010.07.046 – volume: 17 start-page: 2610 issue: 12 year: 2019 ident: 2271_CR19 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2019.02.042 – volume: 45 start-page: 1291 issue: 10 year: 2017 ident: 2271_CR5 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.14030 – volume: 15 start-page: 1427 issue: 9 year: 2017 ident: 2271_CR20 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2017.03.032 – volume: 381 start-page: 1201 issue: 13 year: 2019 ident: 2271_CR14 publication-title: N Engl J Med doi: 10.1056/NEJMoa1900750 – volume: 155 start-page: 1045 issue: 4 year: 2018 ident: 2271_CR22 publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.06.035 – volume: 11 start-page: CD007572 year: 2016 ident: 2271_CR12 publication-title: Cochrane Database Syst Rev – volume: 49 start-page: 674 issue: 4 year: 2014 ident: 2271_CR24 publication-title: J Gastroenterol doi: 10.1007/s00535-013-0829-7 |
| SSID | ssj0017823 |
| Score | 2.424712 |
| Snippet | Backgrounds
Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn’s disease (CD). We aimed to... Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn's disease (CD). We aimed to identify the... Backgrounds Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn's disease (CD). We aimed to... Backgrounds Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn’s disease (CD). We aimed to... Abstract Backgrounds Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn’s disease (CD). We... |
| SourceID | doaj unpaywall pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 195 |
| SubjectTerms | Albumin Biological products Care and treatment Colon Colonoscopy Crohn Disease - drug therapy Crohn's disease Diagnosis Drug utilization Endoscopy Endoscopy, Gastrointestinal Enteroscopy Gastroenterology Hepatology Humans Inflammatory bowel disease Internal Medicine Intestine Laboratories Medicine Medicine & Public Health Methods Monoclonal antibodies Ostomy Pathogenesis Patients Remission Remission (Medicine) Remission Induction Risk factors Serum Albumin Therapeutic drug monitoring Ustekinumab Ustekinumab - therapeutic use |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQDzwOiDcLBRkJiQONmjh-JMdSUVVI5cRKvVl-JOqqW-8q2RXqjb_B3-OXMOM82IBUOHDYSzzJejyf45nMi5C3KrXcl0okzjNMycnQSZi5xDrjasNFyRlmI599lqdz_ulcnO-0-sKYsK48cLdwh6mrvLS8znPLuBDWlLk3oLOYLOr6MY88LcrBmOr9B3Du5UOKTCEPWyTGYFuGPwVW0-QYitX6_3wn7xxKvwdMjl7Te-TONqzN9VezXO4cTCcPyP1eo6RHHScPya0qPCK3z3qf-WNyOQdBXi7C9spYuoldeegSQ4Vaum6QCgOfaQ-GVXNNTfC0Cn6FCSsLRxvsCIff1Ogi0L4Ma0vx-y09blYX4ce37y3t_TxPyPzk45fj06RvsZA4KbJNYjPvi9RaobzyWW6srwsvjAM9R3Hp8sozl6ZWFsJbK0sGh3uV-qoujWJ5LkX-lOyFVaieE2rTuqp9iRUHFRfMWzB-ixqACiajAb1kRrJhxbXr649jG4yljnZIIXUnJQ0S0lFKms_I-_GedVd940bqDyjIkRIrZ8cLgCfd40n_DU8z8g5hoHF_w_QAsl2aAjCJlbL0kULvFJh9wND-hBKE4abDA5B0_15oNahDkhcMdPIZeTMO450Y6xaq1RZpBI_uX3jEsw53I0u5AHO6FDBLNUHkhOfpSFhcxKrh8EAlS_jfgwG7v6Z105oejPj-BxG8-B8ieEnusrhVecKyfbK3abbVK1D9NvZ13OU_AbdAU7E priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZKkXgcEG8WCjISggMNJI4fyQGhUlFVSMuJlXqz_Ejoqouzze4K9sbf4O_xS5jJJmkDVcUhl9hxbM838UzmRcgLFVvucyUi5xmG5CRoJExcZJ1xpeEi5wyjkcef5eGEfzoSR1ukc7dtN3BxoWqH9aQm9ezNj9P1e2D4dw3DZ_LtAr6xCl1pGV4KdKKX89MIC0uhAbatsnGFXIXDK8fqDmN-ZmiAAzLtYmkuHGpwXjVp_f_9eJ87vf72rOzNqzfJ9VWYm_V3M5udO8EObpNbrehJ9zZYuUO2inCXXBu3xvV75GQCFD-ZhtU3Y-myKd9DZ-hTtKDzGnuhhzRtUVPVa2qCp0XwFUa2TB2tsXQc_nyj00DbfK0Lij966X5dHYffP38taGsQuk8mBx-_7B9GbS2GyEmRLCObeJ_F1grllU9SY32ZeWEcCESKS5cWnrk4tjIT3lqZM5ACitgXZW4US1Mp0gdkO1SheESojcui9DmmJlRcMG9BS85KQDTolgYEmBFJuh3Xrk1UjvUyZrpRWDKpN1TSQCHdUEnzEXndPzPfpOm4tPcHJGTfE1NsNzeq-qtuOVbHrvDS8jJNLeNCWJOn3oCwbJJGyVQj8gphoBGaMD3A9iaeARaJKbX0nkIzFuiHsKCdQU8ghhs2d0DSHf41yE2SZwyE9xF53jfjk-gUF4pqhX0Eb-zEMMTDDe76JaUC9O5cwCzVAJGDNQ9bwvS4SS8OAyqZw3t3O-yeTeuyPd3t8f0fJHh8-aKfkBusYUIesWSHbC_rVfEUpL-lfdbw7x-cRFY2 priority: 102 providerName: Scholars Portal – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSFAOiDcLBRkJiQONSBw_kmNZUVVI5cRKvVl-JOqqi7Pa7Krqjb_B3-OXMONkwwZQBYe9xGOvnRl7ZjIznwl5o1LLfalE4jzDkpwMg4SZS6wzrjZclJxhNfLpZ3ky45_OxFkPk4O1MLvx-6yQ71s4PxWmyTL8KfB3bpJboKRkDMzK6RAxAE2Xb4ti_tpvpHgiPv-fp_COGvo9RXKIk94ldzZhaa4uzWKxo4qO75N7vQ1JjzqmPyA3qvCQ3D7to-SPyMUMWHcxD5uvxtJ1vIeHLjA5qKXLFVJhqjPt2d-srqgJnlbBN1iiMnd0hXfA4Vc0Og-0B15tKX6xpdNVcx5-fPve0j6y85jMjj9-mZ4k_aUKiZMiWyc2875IrRXKK5_lxvq68MI4sGwUly6vPHNpamUhvLWyZKDOq9RXdWkUy3Mp8idkLzShekaoTeuq9iViDCoumLfg7hY1iCY4iQYskQnJtm9cux5xHC--WOjoeRRSd1zSwCEduaT5hLwb-iw7vI1rqT8gIwdKxMqOD0CEdL_1dOoqLy2v89wyLoQ1Ze4NWL0mi96impC3KAYadzRMD4S0K0yARSI2lj5SGI8CRw8WdDCiBGa4cfNWkHR_ErQaDCDJCwZW-IS8HpqxJ2a3harZII3gMeALQzzt5G5YUi7AgS4FzFKNJHK05nFLmJ9HnHAYUMkS_vdwK7u_pnXdOz0c5PsfWPD8_0Z_QfZZ3JQ8YdkB2VuvNtVLMOvW9lXczz8Bh-5EUg priority: 102 providerName: Springer Nature – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR3ZbtNAcFVSieOB-wgUtEhIPFCnPvawH0NFVSG18ECk8rTaw26juHbkJELlid_g9_gSZmzHxAVVIPFgKfLOOp7ZmdkZz7GEvJK-YS6R3LMuxJKcAIOEgfWM1TbTjCcsxGrko2NxOGHvT_jJFvmwroUx5_ZUg5NfYkfKqsxHm1Xoea264Yed7c1d1kh8LPYWoGQl5tKGeElwiq6RbcHBOB-Q7cnxx_HnusYIBsDgPlmXzvxxYm97qrv4_66rNzary4mUXTT1FrmxKub64ovO840N6-AOma9RbfJUZqPV0ozs10tdIP8jLe6S261xS8cNN94jW2lxn1w_asP3D8hsAjw1mxarc23osj4giOaYtbSg8wqhMAebtnxZVhdUF46mhSuxdmZqaYWH0-HnPTotaNsRdkHxUzLdr8qz4se37wvahpweksnBu0_7h1572oNnBQ-Wngmci31juHTSBZE2Losd1xZMLsmEjVIXWt83IubOGJGEYGekvkuzRMswigSPHpFBURbpE0KNn6WZS7D5oWQ8dAb88DgDmQHvVYOJNCTBepGVbVuh44kcuapdoliohooKKKhqKio2JG-6OfOmEciV0G-RdzpIbOJd3yirU9XqBOXb1AnDsigyIePc6CRyGsxxHdRurByS18h5ClUNLrRuKyYASWzapcYSA2XggQJCOz1IWAzbH17zrmpV1EKBZSZYHIJ7MCQvu2GciWl3RVquEIazOhINj3jcsHqHUsTBs084vKXsCUEP5_5IMT2rG5jDA6VI4H931-Ly67WuouluJ1J_sQRP_w38GbkZ1kLDvDDYIYNltUqfg725NC9aHfITaph6dg priority: 102 providerName: Unpaywall |
| Title | Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease |
| URI | https://link.springer.com/article/10.1186/s12876-022-02271-4 https://www.ncbi.nlm.nih.gov/pubmed/35448957 https://www.proquest.com/docview/2666482916 https://www.proquest.com/docview/2654289020 https://pubmed.ncbi.nlm.nih.gov/PMC9027696 https://bmcgastroenterol.biomedcentral.com/track/pdf/10.1186/s12876-022-02271-4 https://doaj.org/article/0ced6b4f33b2455ba93da774a1287167 |
| UnpaywallVersion | publishedVersion |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: KQ8 dateStart: 20010101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: ABDBF dateStart: 20010101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: DIK dateStart: 20010101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: RPM dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection (Proquest) customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Open Access Journals customDbUrl: eissn: 1471-230X dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: M48 dateStart: 20011001 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: HAS SpringerNature Open Access 2022 customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: AAJSJ dateStart: 20011201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: C6C dateStart: 20010112 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Za9tAEF4SB3o8lF5p3aZmC4U-NCI69pAeSrFNQijYhFBD2hexh9SYuJIr25S89W_07_WXdGYtKXELpg8W2LuSdzXf7szsXIS8kb5mNpHcMzbEkJwAjYSB8bRRJleMJyzEaOTRWJxO2McLfrFDxk0sDLpVNnui26htafCM_AgYiWBxCNLMh_l3D6tGoXW1KaGh6tIK9r1LMbZL9kLMjNUhe4Pj8dl5a1cAfhg1oTOxOFrA7izRCTfEjwRtaoM9uSz-_-7Vt5jV346UrTX1Prm7Kubq-oeazW4xrJOH5EEtadL-GhqPyE5WPCZ3RrUt_Qm5mgCBr6bF6pvSdOmq9dAZuhAt6LzCXugQTWuQlNU1VYWlWWFLDGSZGlphpTg8a6PTgtbpWRcUz3XpsCovi98_fy1obf95SiYnx5-Gp15desEzggdLTwfWxr7WXFppg0hpm8eWKwPyj2TCRJkNje9rEXOrtUhCYPqZb7M8UTKMIsGjfdIpyiJ7Tqj28yy3CWYilIyHVoNSHOcAYFAlFcgrXRI0bzw1dV5yLI8xS51-Eot0TaUUKJQ6KqWsS96198zXWTm29h4gIduemFHb_VBWX9N6gaa-yazQLI8iHTLOtUoiq0A2VoHTKWWXvEUYpLjuYXgA5XX4AkwSM2ilfYlWK1AHYUIHGz2BGGazuQFSWu8Xi_QG3V3yum3GO9EHrsjKFfbhzJmF4RHP1rhrpxRxULMTDqOUG4jcmPNmSzG9dNnE4YFSJPC_hw12b4a17Z0etvj-DxK82D7pl-Re6BYh88LggHSW1Sp7BcLeUvfIrryQvXodw7ehGPbcwQlcRyyG6_ngC7RPxmf9z38AVdlYZg |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtNAcFW1EoUD4k2gwCKBOFCr9nrXax8q1JZWKW0ihBqpt-0-bBo12CEPVbnxG_wMH8OXMOPYbgNSxKUHX7xje9fz2tl5EfJG-oa7RArPOoYpOQE6CQPrGattprlIOMNs5E43avf4p1NxukJ-1bkwGFZZy8RSULvC4hn5FiiSiMcMdjMfht897BqF3tW6hYauWiu47bLEWJXYcZTOLsGEG28ffgR8v2XsYP9kr-1VXQY8G4lg4pnAudg3RkgnXRBq47LYCW1B1Use2TB1zPq-iWLhjIkSBvot9V2aJVqyMIywawSogDUe8gSMv7Xd_e7nL40fA_RvWKfqxNHWGLSBxKBfhpcE621BHZZdA_7VDdeU49-Bm4339g5Zn-ZDPbvUg8E1BXlwj9ytdrZ0Z06K98lKmj8gtzqV7_4huegBQV308-k3beik7A5EBxiyNKbDEUJhADatiLIYzajOHU1zV2DiTN_SEXamw7M92s9pVQ52TPEcme6NivP894-fY1r5mx6R3o0g4TFZzYs8fUqo8bM0cwlWPpRcMGfACI8zYBgwXTXsj1okqP-4slUddGzHMVClPRRHao4lBRhSJZYUb5H3zTPDeRWQpdC7iMgGEit4lzeK0VdVCQTl29RFhmdhaBgXwugkdBr24joobVjZIu-QDBTKGZgesM48XQIWiRW71I5ELxmYn7CgjQVIQIZdHK4JSVXyaayuuKlFXjfD-CTG3OVpMUUYwUs3NLziyZzumiWFAsz6RMAs5QJFLqx5cSTvn5fVy-GFMkrgu5s17V5Na9k_3Wzo-z9Q8Gz5ol-R9fZJ51gdH3aPnpPbrGRI7rFgg6xORtP0BWw0J-Zlxc2UnN20APkDjN2P5g |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3LbtNAcAVFKnBAvAkUWCQkDtSqH_uwjyUQlUcrDlTqbbUPm0YN68hJhHrjN_g9voSZtWNiQBUccvHObnY9Mzsznhchz2VsmCskj6xLMSUnQSdhYiNjta004wVLMRv58EgcHLN3J_xkI4s_RLuvXZJtTgNWafLLvbmrWhbPxd4CblWJwbMp_iRYQZfJFQbSDXsYjMW49yOA_MvWqTJ_nTcQR6Fq_59384Zw-j1wsveeXidXV36uz7_q2WxDQE1ukhudZkn3W1K4RS6V_jbZPux853fI2TEg9GzqV1-0ocvQnYfOMGRoQecNQmEANO2Iom7OqfaOlt7VmLgytbTBznD4bY1OPe3KsS4ofsel46Y-9T--fV_Qzt9zlxxP3nwaH0Rdq4XICp4sI5M4l8fGcOmkSzJtXJU7ri3oO5IJm5UutXFsRM6dMaJIQciXsSurQss0ywTP7pEtX_vyAaEmrsrKFVh5UDKeOgNGcF4BwYLpqEE_GZFk_caV7eqQYzuMmQr2SC5UiyUFGFIBS4qNyMt-zrytwnEh9CtEZA-JFbTDg7r5rDqGVLEtnTCsyjKTMs6NLjKnQRfWSbAh5Yi8QDJQyOewPSDdNl0BDokVs9S-RC8VmH9woJ0BJCDDDofXhKS6-2GhQC0SLE9BNx-RZ_0wzsSYN1_WK4ThLLiBYYn7Ld31R8o4mNUFh13KAUUOzjwc8dPTUD0cFpSigP_dXdPur21d9E53e_r-BxQ8_L_Vn5Ltj68n6sPbo_ePyLU08CeL0mSHbC2bVfkY9L6leRJY-ydMXU-I |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR3ZbtNAcFVSieOB-wgUtEhIPFCnPvawH0NFVSG18ECk8rTaw26juHbkJELlid_g9_gSZmzHxAVVIPFgKfLOOp7ZmdkZz7GEvJK-YS6R3LMuxJKcAIOEgfWM1TbTjCcsxGrko2NxOGHvT_jJFvmwroUx5_ZUg5NfYkfKqsxHm1Xoea264Yed7c1d1kh8LPYWoGQl5tKGeElwiq6RbcHBOB-Q7cnxx_HnusYIBsDgPlmXzvxxYm97qrv4_66rNzary4mUXTT1FrmxKub64ovO840N6-AOma9RbfJUZqPV0ozs10tdIP8jLe6S261xS8cNN94jW2lxn1w_asP3D8hsAjw1mxarc23osj4giOaYtbSg8wqhMAebtnxZVhdUF46mhSuxdmZqaYWH0-HnPTotaNsRdkHxUzLdr8qz4se37wvahpweksnBu0_7h1572oNnBQ-Wngmci31juHTSBZE2Losd1xZMLsmEjVIXWt83IubOGJGEYGekvkuzRMswigSPHpFBURbpE0KNn6WZS7D5oWQ8dAb88DgDmQHvVYOJNCTBepGVbVuh44kcuapdoliohooKKKhqKio2JG-6OfOmEciV0G-RdzpIbOJd3yirU9XqBOXb1AnDsigyIePc6CRyGsxxHdRurByS18h5ClUNLrRuKyYASWzapcYSA2XggQJCOz1IWAzbH17zrmpV1EKBZSZYHIJ7MCQvu2GciWl3RVquEIazOhINj3jcsHqHUsTBs084vKXsCUEP5_5IMT2rG5jDA6VI4H931-Ly67WuouluJ1J_sQRP_w38GbkZ1kLDvDDYIYNltUqfg725NC9aHfITaph6dg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ustekinumab+trough+levels+predicting+laboratory+and+endoscopic+remission+in+patients+with+Crohn%E2%80%99s+disease&rft.jtitle=BMC+gastroenterology&rft.au=Hirayama%2C+Hisashi&rft.au=Morita%2C+Yasuhiro&rft.au=Imai%2C+Takayuki&rft.au=Takahashi%2C+Kenichiro&rft.date=2022-04-21&rft.pub=Springer+Nature+B.V&rft.eissn=1471-230X&rft.volume=22&rft.spage=1&rft_id=info:doi/10.1186%2Fs12876-022-02271-4 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-230X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-230X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-230X&client=summon |